Santhera’s AGAMREE Gains Fast-Track Status in South Korea

Event summary

  • AGAMREE (vamorolone) received Orphan Drug and GIFT (Global Innovative Products on Fast Track) designations in South Korea for Duchenne muscular dystrophy (DMD).
  • The GIFT designation could reduce the regulatory review timeline from 120 to 90 working days.
  • Nxera Pharma plans to submit a Marketing Authorization Application in South Korea during 2026.
  • Santhera will receive sales and milestone payments and royalties on net sales of AGAMREE in the licensed territories.

The big picture

Santhera’s AGAMREE is gaining momentum in key Asian markets, following its approvals in the U.S., EU, and China. The GIFT designation in South Korea underscores the drug’s strategic importance in addressing unmet medical needs in rare diseases. With Nxera Pharma leading commercialization efforts, Santhera stands to benefit from expanded market access and revenue streams in high-growth regions.

What we're watching

Regulatory Speed
Whether the GIFT designation will significantly accelerate AGAMREE’s market entry in South Korea.
Commercial Execution
How Nxera Pharma will leverage the fast-track status to drive adoption in a market with no current DMD treatment options.
Revenue Impact
The pace at which AGAMREE generates milestone payments and royalties for Santhera in South Korea.